These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 34631568

  • 1. Miller-Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy.
    Wang L, Luo R, Lu Q, Jiang K, Hong R, Lee K, Zhang P, Zhou D, Wang S, Xu F.
    Front Oncol; 2021; 11():735670. PubMed ID: 34631568
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X, Rao J, Yang W, Shui R.
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy.
    Ji L, Chen X, Qian X, Xiao M, Li Q, Li Q, Wang J, Fan Y, Luo Y, Chen S, Ma F, Xu B, Zhang P.
    Breast; 2024 Dec; 78():103792. PubMed ID: 39232268
    [Abstract] [Full Text] [Related]

  • 5. A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems (CSBrS-026).
    Xiang H, Xin L, Ye J, Xu L, Zhang H, Zhang S, Liu Y.
    Chin J Cancer Res; 2023 Dec 30; 35(6):702-712. PubMed ID: 38204446
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer.
    Wang W, Liu Y, Zhang H, Zhang S, Duan X, Ye J, Xu L, Zhao J, Cheng Y, Liu Q.
    Gland Surg; 2021 Dec 30; 10(12):3211-3221. PubMed ID: 35070881
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N, Enomoto Y, Inakami K, Yanagisawa T, Iguchi C, Aono T, Nomura T, Yamamoto H, Kasugai T, Shiba E.
    Oncology; 2020 Dec 30; 98(1):35-41. PubMed ID: 31574500
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.
    Breast; 2014 Aug 30; 23(4):466-72. PubMed ID: 24742606
    [Abstract] [Full Text] [Related]

  • 14. Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.
    Zhang S, Liu Y, Liu X, Liu Y, Zhang J.
    Cancers (Basel); 2023 Feb 10; 15(4):. PubMed ID: 36831499
    [Abstract] [Full Text] [Related]

  • 15. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
    Wang X, Cai L, Ye F, Li M, Ma L, Geng C, Song Z, Liu Y.
    Medicine (Baltimore); 2019 Sep 10; 98(36):e16937. PubMed ID: 31490377
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. RS7435335 located in the UGT2B7 gene may be a possible genetic marker for the clinical response and prognosis of breast cancer patients receiving neoadjuvant chemotherapy.
    Mou P, Wang H, An L, Yin Q, Chang J.
    J Cell Biochem; 2019 May 10; 120(5):7167-7173. PubMed ID: 30552707
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Iwase M, Ando M, Aogi K, Aruga T, Inoue K, Shimomura A, Tokunaga E, Masuda N, Yamauchi H, Yamashita T, Iwata H.
    Breast Cancer Res Treat; 2020 Apr 10; 180(3):687-694. PubMed ID: 32140811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.